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Zusammenfassung 
 
Einleitung UDP-glucuronosyltransferasen (UGTs) bilden eine Familie von u. A. 
humanen Metabolisierungsenzymen. UGTs transferieren Glucuronsäure vom 
Cosubstrat (UDP-Glucuronsäure) auf ein Substrat. Dadurch wird das Substrat 
hydrophiler und somit besser ausscheidbar. 
  Um die Verfügbarkeit von Arzneistoffen im Körper zu ermitteln und um 
Nebenwirkungen zu verhindern, werden in vitro Tests entwickelt, die es 
ermöglichen die katalytische Aktivität der UGTs vorherzusagen. Ältere 
Publikationen zeigten, dass das Zugeben von Rinderserumalbumin (BSA) bei 
in vitro Tests, die Aktivität dieser Enzyme steigerte. Diese Wirkung entsteht 
wahrscheinlich durch das Entfernen von kompetitiv inhibierenden Fettsäuren. 
Durch klinische Studien wurde nachgewiesen, dass auf diese Weise erworbene 
Daten besser mit in vivo Daten übereinstimmen. 
 
Ziele Mit dieser Arbeit wollten wir die Wirkung von BSA auf die 
Glucuronidierung von 4-Methylumbelliferon (4MU) und Entacapon durch eine 
Gruppe von unerforschten UGT Isoformen (UGTs 1A7, 1A8, 1A10, 2A1 und 
2A15) analysieren. Die Glucuronidierung von 4MU durch UGT1A9 wurde 
durchgeführt, um unser System mit schon publizierten Daten zu vergleichen. 
Zum selben Zweck wurden auch kommerziell verfügbare humane 
Lebermikrosomen (HLM) und Darmmikrosomen (HIM) getestet. 
 
Ergebnisse und Diskussion Mit Ausnahme der Kinetiken von 4MU durch 
HIM, konnten wir zeigen, dass alle getesteten Enzyme von einem nicht-
kompetitiven Inhibitor (genauer „mixed type Inhibitor“) beeinflusst wurden. 
Dadurch dass die Entfernung des Inhibitors  (vermutlich eine Mischung an 
Fettsäuren) eine weitere Bindetasche für das Substrat freistellte, folgerten wir, 
dass das Substrat und die Fettsäuren um die selbe inhibierende Bindetasche 
konkurrieren. Angesichts der Tatsache, dass Fettsäuren auch an die 
katalytische Tasche binden können, vermuteten wir, dass diese, dem Anschein 
nach ähnliche Taschen, die homologen Taschen eines Enyzmdimers 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
  
iv 
darstellen. Das Auftreten von Dimeren in UGTs wurde schon in früheren 
Publikationen postuliert, aber noch nicht vollkommen bestätigt. 
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Abstract 
Introduction UDP-glucuronosyltransferases (UGTs) are a family of 
metabolizing enzymes present in the human body. The UGTs transfer a moiety 
of glucuronic acid from the cosubstrate UDP-glucuronic acid (UDP-GA) to the 
substrate in order to make it more hydrophilic and therefore better excretable 
from the body.  
In vitro tests for the prediction of the catalytic activity of UGTs are being 
developed to analyze the availability of drugs in the body and to reduce 
eventual side effects. It has been found, that the addition of BSA to the 
incubation mixture increases the activity of these enzymes in vitro, probably by 
removing competitively inhibiting fatty acids (FAs). Data retrieved by this 
method have shown to be more consistent to the data evaluated in vivo. 
 
Aims Our objectives were to test the effect of BSA on the glucuronidation of 4-
methylumbelliferone (4MU) and entacapone by an untested group of UGTs 
which includes the UGTs 1A7, 1A8, 1A10, 2A1 and 2B15. The glucuronidation 
of 4MU by UGT1A9 was performed to compare our system with the previously 
published data. Also the commercially available HLM and HIM have been 
tested for the purposes of comparison. 
 
Results and discussion With the exception of the kinetics of 4MU by HIM, all 
our tested enzymes were shown here to be inhibited by a mixed type inhibitor. 
Contrary to earlier findings from another laboratory, the inhibitor in our system 
was not only binding to the same binding site as the aglycone substrate. Given 
by the observation that the inhibitor(s) removal increased or even unmasked 
the presence of a second substrate binding site, we concluded that the inhibitor 
(possibly fatty acids) and the substrate have affinity to both a catalytic and an 
inhibititory binding site. This suggestion is in agreement with the possibility that 
UGTs can form homo- and hetero-dimers, and that interactions occur between 
the two monomers within the dimeric UGT. 
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1 Introduction 
 
This thesis talks about UDP-glucuronosyltransferases (UGTs), a family of 
enzymes present in various organs and tissues of the human body. UGTs 
catalyze the attachment of the glucuronic acid moiety from the donor UDP-
glucuronic acid (UDP-GA) to a suitable nucleophilic group on the aglycone 
substrate molecule. This conjugation, also called glucuronidation, makes the 
substrate more water soluble and better excretable from the body. The present 
work tries to find a way to improve experimental methods for the evaluation of 
the activity of the UGTs, thereby also answering some questions about the 
mechanism of these enzymes. 
 
1.1 Pharmacokinetics, (L)ADME scheme 
The aim of pharmacokinetic studies is to investigate the pathway of a 
substance through the human body. There are 4 steps, which can influence the 
time between the uptake of the substance and its elimination. The drug, or non-
drug xenobiotic, has to enter first into the blood circulation (Absorption), from 
where it can be transported to various tissues and organs (Distribution). The 
modification of the substrate during the process (Metabolism) is an important 
step towards possible inactivation and better elimination (Excretion) of the 
compound. In the last few years, some formulations have been developed that 
are able to modify the release of the drug. This may add a Liberation step to 
the pathway, forming the abbreviation (L)ADME. 
 
1.1.1 Metabolism 
Many exogenous and endogenous compounds the human body has to deal 
with are lipophilic (fat soluble). Since the elimination of substances is performed 
through a hydrophilic medium (mainly urine and bile), lipophilic compounds 
have to be converted into more polar molecules first. This modification is 
generally achieved through metabolism. In addition to enhanced excretion by 
metabolism, most of the compounds lose or decrease their biological activity by 
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getting modified. The metabolism system is, therefore, an important step for the 
detoxification. There are some compounds, however, that are activated by 
biotransformation, even by glucuronidation. One example for this is the 
analgesic drug codeine that is metabolized by CYP2D6 into the active form 
morphine (Caraco et al., 1999). Further metabolism by UGT2B7 forms the even 
100 times more potent compound morphine-6-glucuronide (Paul et al., 1989). 
Codeine can, therefore, be defined as a prodrug. 
 
Drug metabolism in the human body is executed by several groups of enzymes 
that catalyze different reactions. This process is traditionally divided into two 
“phases”, I and II. The ‘Phase I’ enzymes are in charge of the functionalisation 
of the compound, where polar functional groups are added, or already present 
groups are unmasked. Such functional groups include hydroxyl (-OH), carboxyl, 
(-CO2H) or amino (-NH2) moieties. The most important functionalisation 
enzymes by number and activity are the Cytochromes P450 monooxygenases 
(CYP450), which are also the most important drug metabolizing enzymes in 
general. 
 
The ‘Phase II’ enzymes catalyze conjugation reactions. Polar endogenous 
compounds such as glucuronic acid, sulfate or glutathione are covalently linked 
to a suitable functional group of the substrate. An exception in this group are 
the acetyltransferases that catalyze the transfer of an acetyl group to the 
substrate. The formed product gets therefore more lipophilic. The main Phase II 
enzymes are the UDP-glucuronosyltransferases (UGTs). 
 
Since conjugation is performed onto functional groups, phase II enzymes 
mainly metabolize compounds only after fictionalization by phase I enzymes. 
However, in many cases compounds already have suitable functional groups 
and do not require phase I reactions. In addition, many compounds are 
secreted already after phase I metabolism, without further conjugation, and 
already hydrophilic compounds can be eliminated without any metabolism at 
all. 
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1.2 UDP-glucuronosyltransferases 
1.2.1 Function and mechanism 
UGTs are involved in the metabolism of a wide range of exogenous  
compounds (xenobiotics) such as drugs, dietary chemicals and environmental 
pollutants, as well as endogenous compounds, including bilirubin, bile acids, 
fatty acids, steroid hormones, thyroid hormones and fat soluble vitamins 
(Miners and Mackenzie, 1991; Burchell et al., 1995; Radominska-Pandya et al., 
1999; Tukey and Strassburg, 2000; Kiang et al., 2005). The reaction in which 
the glucuronic acid from UDPGA (UDP- Glucuronic acid) is covalently linked to 
the substrate is referred to as glucuronidation. The linkage can be performed 
on different functional groups, containing oxygen or nitrogen. O-glucuronidation 
can occur on alcohols (ROH) or phenols (ArOH), while N-glucuronidation is 
carried out on either primary amines (RNH2), secondary amines (RNR’H), or 
tertiary amines. Aromatic and heterocyclic amines (RNR’R’’) can also be 
conjugated. 
 
The reaction catalyzed by UGT occurs on the C1 atom of the glucuronic acid 
and follows a second order nucleophilic substitution (SN2) mechanism (Miners 
and Mackenzie, 1991; Radominska-Pandya et al., 1999; Tukey and Strassburg, 
2000). The heteroatom in the functional group of the substrate presents one or 
two free electron pairs that can bind to the C1 atom. The main evidence that the 
reaction follows the SN2 nucleophilic substitution mechanism is that it induces 
an inversion of the previous α- conformation into the β-D-glucuronide (Figure 
1).  
 
 
Figure 1. Glucuronidation of substrate by SN2 mechanism. The nucleophilic 
heteroatom of the substrate (B.) binds to the C1 atom of the glucuronic acid, removing 
the UDP (D.) from the linkage. 
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1.2.2 Catalytic mechanism 
The glucuronidation of a substance by UGTs requires the presence of the 
cosubstrate UDPGA. Since the reaction yields two products out of two 
substrates (Figure 1), it can be defined as bi bi mechanism. It is still unclear, 
however, if the reaction follows a certain order for the binding of cosubstrate 
and aglycone. There are some data suggesting a compulsory ordered 
mechanism, where UDPGA has to bind to the free enzyme first (Figure 2) 
(Luukkanen et al., 2005; Patana et al., 2008), but a random ordered 
mechanism has not been fully excluded (see 1.3.3). 
 
 
Figure 2. Catalytic cycle of UGTs 
A. Glucuronidation by a compulsory ordered bi bi mechanism with UDPGA as first 
binding substance. Box B. shows two possible “dead end” or non-productive 
complexes due to either binding of aglycone substrate before UDPGA (x), or binding of 
the reaction product, UDP, instead of the co-substrate, UDPGA (y). In the case of 
either “dead end” enzymes further activity is only possible after the dissociation of the 
inhibiting substance. Complex a. is the conformation believed to be responsible for the 
atypical kinetic “substrate inhibition” (see 1.3.1) 
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1.2.3 Structure and Heterogeneity 
The UGT protein is about 500-505 amino acids long, following the removal of 
the first 25 residues, the signal sequence, that directs the newly synthesized 
protein to the endoplasmic reticulum. The UGTs are probably dimeric proteins 
and it was suggested that they could form both homo-dimers and hetero-
dimers, but more structural evidence is needed to verify this (Finel and Kurkela, 
2008). The UGT monomer was suggested to have four different substructures, 
two large ones, the N-terminal and C-terminal domains, and two smaller ones 
that follow the C domain, the envelope helices and the transmembrane 
segment (Laakkonen and Finel, 2009). Apart from the more variable N- 
terminal domain, all substructures are very similar in all the isoforms, and 
among the UGT1 as, as well as between UGT2A1 and UGT2A2, they are 
identical due to exon sharing (Mackenzie et al., 2005). The C-domain contains 
the binding site for the common co-substrate UDPGA, although some residues 
in the N-terminal domain may also contribute to the co-substrate binding (Miley 
et al., 2007; Patana et al., 2007). It is understandable, therefore, that the 
binding site for the aglycone substrate is located in the N-terminal domain.  
 
The aglycone substrate selectivity of individual UGT isoforms can sometimes 
be overlapping. The presence of backup proteins allows to metabolize via a 
secondary pathway in cases of miss functions of single isoforms. Diseases or 
drug-drug interactions caused by modifications of UGTs are, therefore, not very 
common. An important exception to this general rule is the Crigler- Najjars 
syndrome, caused by modifications of UGT1A1. The hemoglobin 
decomposition product bilirubin is a major substrate of UGT1A1, the only 
human enzyme that catalyzes its conjugation with glucuronic acid, a pre-
requisite for its excretion (Petit et al., 2008). There are several modifications of 
UGT1A1 that can lower or abolish bilirubin metabolism. This can lead to 
elevated concentrations of unconjugated bilirubin in the blood and, 
subsequently, to severe jaundice and kernicterus. 
 
To date 22 active UGT-encoding genes have been identified (Miners et al., 
2004; Mackenzie et al., 2005) belonging to 4 different families. The relevant 
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families for this study, and for drug glucuronidation, are UGT1 and UGT2 that, 
together, include 19 different isoforms. Families UGT3 and UGT8 are of minor 
relevance. 
 
The large human UGT1 (This family is commonly called UGT1A, but no other 
UGT1 subfamilies are known) gene is located on chromosome 2q37. The 
variability of the different UGT1A proteins is given by the alternative splicing of 
9 first exons, with 4 exons that are shared by all of them. Each of the 9 first 
exons forms, together with the four common exons (2-5), one of the 9 
functional transcripts UGT1A1 and UGT1A3-1A10. The four common exons 
generate the C-terminal part (Mackenzie et al., 2003), while the variable exon 1 
is encoding the N- terminus. 
 
The UGT2 family is encoded by separate genes located in chromosome 4q13 
and is further divided in two subfamilies, UGT2A and UGT2B (Mackenzie et al., 
2005). Those include three (2A1, 2A2 and 2A3) and seven (2B4, 2B7, 2B10, 
2B11, 2B15, 2B17 and 2B28) members respectively. Each of the UGT2 genes 
has all its exons, with the exception of UGT2A1 and UGT2A2 that share the 
exons that encode the C-terminal half in a similar way to the exon sharing 
among the UGT1As. The UGT2A subfamily has a lower importance in systemic 
metabolism. UGT2A1 and UGT2A2 are mainly found in the olfactory epithelium 
(Jedlitschky et al., 1999; Somers et al., 2007; Sneitz et al., 2009), while 
UGT2A3 is expressed in the small intestine, liver and adipose tissue (Court et 
al., 2008). On the other hand, members of the UGT2B subfamily play important 
roles in the metabolism of drugs and endogenous compounds. 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes
Figure 3. Family tree of human UGTs and location of the exons, needed for their 
translation (from Guillemette et al., 2010) 
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1.2.4 Tissue specificity 
UGTs can be found in different tissues at different concentrations (Figure 4). 
The expression vary due to differences between individuals (Nishimura and 
Naito, 2006; Izukawa et al., 2009) and it is worth noting that the figure below is 
from mRNA determinations that is not always identical with the level of active 
proteins in the tissue. 
 
 
 
 
Figure 4. Expression levels of UGT1A and UGT2B families in human tissues. 
(from Ohno and Nakajin, 2009) 
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1.3 Enzyme Kinetics 
1.3.1 Michaelis Menten equation and atypical kinetics 
Enzyme kinetic studies are commonly used to analyze the activity of enzymes, 
to get insights into their mechanism, and the effect of different substances on 
the catalysis. The modality of the reaction has first been described by Michaelis 
and Menten (1913) and developed further by Briggs and Haldane (1925): 
 
Equation 1 
E + S ES E + P
k1
k
-1
k2
 
 
The assumptions are that the Enzyme (E) and the substrate (S) form a binary 
ES complex in order to yield the product (P) and restore free enzyme. The 
binary complex is usually stabilized by nonconvalent forces, including 
electrostatic interactions, hydrogen bonds, hydrophobic forces and van der 
Waals forces (Copeland, 2000). These weaker bonds allow a reversible 
equilibrium between the complex and the free forms of enzyme and substrate. 
This state of balance is described by rate constants k1 and k-1. The scheme 
assumes practical irreversible catalysis and, therefore, no reverse reaction is 
shown for the product formation. The rate constant for the catalysis and product 
release is given the symbol k2. 
 
There are two constants used to compare different kinetics. The Km constant is 
defined by:  
 
Equation 2 
( )
1
12
k
kkKm −
+
=
 
 
Even though it is often used as a parameter for the substrate affinity to the 
enzyme, it must be noticed, that k2 determines the rate of formation of the 
product. Therefore, Km is only equal affinity if k2 is much smaller than k-1. The 
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constant Vmax stands for the maximum reaction velocity, reached at a saturated 
concentration of substrate. It is defined by the following equation: 
 
Equation 3 
[ ]02max EkV ×=  
 
where [E0] is the total concentration of enzyme present. 
 
The Michaelis-Menten equation, modified by Briggs and Haldane (1925), 
combines the two constants, Vmax and Km, in a single equation: 
 
Equation 4 
[ ]
[ ]SK
SV
m +
=
maxν
 
 
where ν is the rate of product formation. 
 
Visualized as a graph, where the rate of product formation is plotted versus the 
substrate concentration, the Michaelis-Menten equation forms a hyperbolic 
curve. The plateau of this curve indicates the Vmax, whereas the halfway 
between V0 and Vmax can be used to determine the Km. 
 
As shown in Figure 5, however, it is not always possible to describe kinetics by 
the simple Michaelis-Menten equation. In many cases atypical kinetics models, 
such as substrate inhibition, activation, autoactivation or biphasic mechanism 
(Hutzler et al., 2001), would fit best. Unfortunately, Vmax and, particularly, Km 
can not be used for meaningful comparisons of the reactions that proceed 
according to different kinetic models. 
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Figure 5. Graphs of Michaelis- Menten (A) and atypical kinetics (B, C, D), where 
the rate of product formation is plotted against the substrate concentration. The 
smaller graphs are samples of the Eadie-Hofstee diagram (from Hutzler and Tracy, 
2002) 
 
The shapes of the curves in a graph, where the velocity is plotted versus the 
substrate concentration, are usually not as clear as shown in Figure 5. 
Sometimes it is difficult or even impossible to detect an atypical kinetic 
mechanism by looking at the graph of the simple dependence of reaction rate 
on substrate concentration. Eadie-Hofstee plot is a useful method for better 
visualization of these phenomena. Atypical kinetics will deviate from the straight 
line (A) of the Michaelis-Menten kinetics in an Eadie-Hofstee plot, when the 
rate of product formation is plotted versus ν/[S] in a typical manner. If the line is 
curved as shown in diagram C, the enzyme is affected by substrate inhibition. A 
curved as in B, suggests (auto-) activation. Biphasic kinetics are depicted by a 
buckle in the middle of the line (D). A combination of these kinetic patterns is 
also possible. Atypical kinetics occur in enzymes with multiple binding sites and 
will be further described at chapter 1.3.3. 
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Given the availability of modern computer software, it is not necessary any 
more to plot linear transformations to evaluate kinetic parameters. Graphs can 
still be used, however, for fast and easy visualization of kinetics analyses. 
 
1.3.2 Enzyme inhibition 
The studies of enzyme inhibition are very important for understanding the 
enzyme structure and mechanism, for the development of new drugs and for 
evaluation of drug-drug interactions. An inhibitor is a substance that decreases 
the activity of an enzyme towards its substrate. Given by the strength of 
inhibitor binding the enzyme, we can distinguish between reversible and 
irreversible inhibition. A reversible inhibitor is present in an equilibrium between 
the bound and free states, whereas an irreversible inhibitor forms a permanent 
complex with the enzyme. A reactivation of the enzyme is in the latter case not 
possible. The influence of irreversible inhibitor on the cell or organ lasts until 
new enzyme molecules are available.  
 
1.3.2.1 Reversible inhibition models 
 
Equation 5 
α
.L
E + S + I ES + I E + P + I
EI + S ESI
Ki
Ks Kp
 
 
The classification into competitive, noncompetitive and mixed-type inhibition is 
given by the affinity of the inhibitor to the free enzyme and/or the ES complex 
(Copeland 2005). It is possible to use the constant α to describe the different 
binding behaviors. An inhibitor that binds to the same binding site as the 
substrate is defined as competitive. This would result in α = ∞. The dissociation 
constant between the inhibited and the free enzyme is Ki. In some cases, 
however, also the inhibitor itself can be processed
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different substrates of the same enzyme can act as competitive inhibitors to 
each other.  
 
If α << 1, the inhibition type is defined as uncompetitive. The inhibitor binds only 
to the ES complex, using a different binding site than the substrate. As a result 
of inhibitor binding, the enzyme-substrate complex changes its conformation, 
losing or decreasing its affinity to the substrate or reducing its catalytic activity. 
This mechanism is commonly referred to as allosteric modulation. The 
dissociation constant for the ternary ESI complex is αKi. 
 
A noncompetitive inhibitor can bind to both, the free enzyme and the ES 
complex, also by acting as an allosteric modulator. There is still not a 
standardized nomenclature about this mechanism. Some scientific publications 
assign the term noncompetitive only to reactions where α = 1, where the 
inhibitor has the same affinity to the free enzyme as to the ES complex. If α > 1 
(higher affinity to E) or α < 1 (higher affinity to ES), but α ≠ 1, the term mixed 
type inhibition, could be more precise. In any case, the binding affinity of the 
inhibitor must be described by both, Ki and αKi. 
 
Performing steady-state kinetic experiments, where increasing concentrations 
of substrate are added to the reaction and determining the initial reaction 
velocity (V), it is possible to compare the activity of an enzyme in presence and 
absence of inhibitors. The effect of inhibitor presence on the Km and Vmax 
constants can tell the mechanism and magnitude of inhibition. The different 
inhibition types and their affect on the two parameters are shown in Table 1. 
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Table 1. The effect of inhibitors on kinetic parameters 
Parameter Type of Inhibition 
 Competitive 
α = ∞ 
Noncompetitive/ 
Mixed Type 
α > 1 
Noncompetitive 
α = 1 
Noncompetitive/ 
Mixed Type 
α < 1 
Uncompetitive 
α << 1 
Km Increases 
linearly with 
increasing [I] 
Increases 
curvilinearly with 
increasing [I] 
No effect Decreases 
curvilinearly with 
increasing [I] 
Decreases 
curvilinearly with 
increasing [I] 
Vmax No effect Decreases 
curvilinearly with 
increasing [I] 
Decreases 
curvilinearly with 
increasing [I] 
Decreases 
curvilinearly with 
increasing [I] 
Decreases 
curvilinearly with 
increasing [I] 
Inhibited 
enzyme 
state 
E E > ES E = ES E < ES ES 
 
As mentioned above, it is possible to draw a graph where the rate of product 
formation (V) is plotted versus the substrate concentration [S]. Comparing the 
kinetics of the inhibited and not inhibited enzyme it is possible to see changes 
of Km and Vmax. Nevertheless, it is not always easy to evaluate the two 
parameters by the hyperbolic curve. Therefore, linearizations, such as the 
double reciprocal Lineweaver-Burk plot, have been developed to facilitate the 
estimation of the kinetic constants and inhibition types (Cortes et al., 2001). If 
1/V is plotted versus 1/[S], 1/Vmax is located at the point of interception of the 
line with the y-axis. Km can be evaluated ether from the slope of the line, or 
from the interception point with the abscissa (x-axis) (Figure 6). 
 
Keeping in mind that a competitive inhibitor does not affect Vmax, one can 
assume that the line of an inhibited enzyme intercepts the line of the 
uninhibited enzyme at 1/[S] = 0. If the lines are crossing each other on the x-
axis, the inhibitor is noncompetitive (α = 1), whereas if the graph displays two 
parallel lines, an uncompetitive inhibitor is inhibiting the tested enzyme. For the 
mixed type inhibition, the intersection occurs in quadrant II (y|-x) or quadrant III 
(-y|-x) if α >1 or <1, respectively. 
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Figure 6. Graphs of A. competitive, B. noncompetitive (α = 1), C. mixed type (α > 
1), and D. uncompetitive inhibition. 
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1.3.3 Enzyme reactions with multiple substrates or multiple site kinetics 
 
The reaction mechanism by which one substrate is needed to form one 
product, is useful for understanding enzyme kinetics, but is not very common in 
nature. It is common to encounter enzymatic reactions involving two or more 
substrates and at least two products (Copeland 2000). The amount of chemical 
entities present in the reaction is denominated by the Latin prefixes uni, bi, ter 
and so on. A simple model for a good demonstration is the bi bi mechanism, 
where two substrates are needed to form two products. 
 
Equation 6 
E + AX + B E + A + BX
 
 
where X is the moiety that is being transferred from substrate A to substrate B. 
This simple model is at the basis of the explanation for at least three different 
mechanisms, namely, random ordered, compulsory ordered (Figure 7) and 
double-displacement or “Ping- Pong” bi bi mechanism. 
 
 
Figure 7. Schemes of a random ordered (A) and compulsory ordered mechanism 
(B) (from Luukkanen et al., 2005) 
 
In contrast to the random ordered mechanism, a compulsory order reaction has 
a defined sequence of binding and/or leaving of the substrates and products, 
respectively. Given by that, an inhibition by the second-binding substrate, B, 
can occur and be visible at higher concentrations. B can in this case bind to the 
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free enzyme, inhibiting the binding of substrate A and preventing turn over. This 
mechanism can explain the atypical kinetic substrate inhibition (Figure 5). 
 
While in the mechanisms described above the ternary complex E•AX•B has to 
be formed to create the products, in the double-displacement mechanism A 
and B are never bound to the enzyme at the same time. A dissociation of A has 
to occur to allow the binding of B. 
 
In some cases, a substrate can bind to different sites, forming the complex 
SES. This could either increase or decrease the enzyme activity, described as 
positive or negative homotropic cooperativity respectively (Houston and 
Kenworthy, 2000). This mechanism may also be involved in atypical kinetics 
due to substrate inhibition. It is possible that the SES complex can still generate 
product, but at lower rates than the ES complex. This type of substrate 
inhibition is generally referred to as partial inhibition. If the substrate is 
enhancing the activity, instead, the mechanism is shaped by autoactivation. 
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1.4 In vivo – in vitro correlation 
 
In vivo – in vitro correlations should allow a prediction of drug metabolism in the 
body at quantitative and qualitative levels from in vitro assays with suitable 
samples such as recombinant enzymes or liver microsomes. Since it is not 
possible and not ethical to execute extensive characterizations of human drug 
metabolism in vivo, in vitro approaches have been developed to enhance the 
safety and efficacy of pharmaceutical therapies (Houston, 1994; Miners and 
Birkett, 1998; Iwatsubo et al., 1997; Boase and Miners, 2002; Miners, 2002). 
Most of the drug-metabolizing enzymes, such as the CYPs and UGTs, often 
exhibit partial overlapping activities. To examine such overlaps and also to 
learn about the effects of genetic polymorphism in these enzymes, it is 
necessary to prepare single isoforms and test their behavior in vitro. Also the 
analysis of mixtures of enzymes present in the respective tissues can be a 
helpful tool to investigate the metabolism rates in different organs. 
 
A common parameter for comparisons of metabolic activities is the intrinsic 
clearance CLint that is defined by the kinetic parameters: 
 
Equation 7 
mK
VCL maxint =  
 
CLint is, however, just a measure of the efficiency of the metabolic enzymes. To 
obtain complete in vivo data by calculations, other parameters, such as the 
blood flow through the organ, the uptake into the organ and the fraction 
unbound fu, have to be taken in consideration. 
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1.4.1 The “albumin effect” 
Despite the importance of the in vivo – in vitro correlation for drug development, 
several publications claimed a general trend of under- prediction for CYPs and 
UGTs metabolism, when in vitro CLint derived from liver microsomes or 
recombinant enzymes are used to forecast the in vivo CLint (Houston and 
Carlile, 1997; Iwatsubo et al., 1997; Ito et al., 1998; Naritomi et al., 2001; 
Miners et al., 2004; Engtrakul et al., 2005; Ito and Houston, 2005; Cubitt et al., 
2009). Interestingly, it was found that in the presence of bovine serum albumin 
(BSA) during microsomal incubations, the in vitro CLint seems to get closer to 
the true rates of in vivo metabolism (Ludden et al., 1997; Carlile et al., 1999; 
Baba et al., 2002; Tang et al., 2002; Wang et al., 2002; Rowland et al., 2006; 
Rowland et al., 2008a; Rowland et al., 2009; Uchaipichat et al., 2006; Raungrut 
et al., 2010). When it comes to UGTs, (Rowland et al., 2008b) it was shown 
that increased activity of UGT2B7 could be achieved by the addition of BSA, 
probably due to its activity in the removal of fatty acids (FA) that may be 
released during microsomes preparation. FA are metabolized via different 
CYPs from the CYP2 and CYP4 families (Hoagland et al., 2001, Maier and 
Roman, 2001) and UGTs from the UGT1A and UGT2B families (Turgeon et al., 
2003, Little et al., 2004, Little et al., 2002). Being substrates of these enzymes, 
they could also bind and act as competitive inhibitors with respect to other 
substrates (Tsoutsikos et al., 2004; Rowland et al., 2006). As shown in Table 2, 
in most of the recombinant UGT isoforms that were tested in this study, BSA 
seemed to remove (also) a competitive inhibitor. 
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Table 2. Effect of BSA on recombinant UGT isoforms 
Enzyme Substrate Inhibitor type Kinetics model 
1A1 4-Metylumbelliferone1 no inhibitor Control: Michaelis Menten 
BSA: two site model – 
autoactivation and substrate 
inhibition (Segel 1975; Houston 
and Kenworthy, 2000) 
1A4 Lamotrigine4 mixed type inhibitor Control: Michaelis Menten 
BSA: Michaelis Menten 
1A6 4-Metylumbelliferone1 no inhibitor Control: Michaelis Menten 
BSA: two site model – 
autoactivation (Segel 1975, Huston 
and Kenworthy 2000) 
1A9 4-Metylumbelliferone1 competitive inhibitor Control: Michaelis Menten 
BSA: Michaelis Menten 
Propofol1 competitive inhibitor Control: Michaelis Menten 
BSA: Michaelis Menten 
2B4 Codeine3 competitive inhibitor Control: Sigmoidal kinetics 
BSA: Sigmoidal kinetics (amplified) 
2B7 Zidovudine2,4 competitive inhibitor Control: Michaelis Menten 
BSA: Michaelis Menten 
4-Metylumbelliferone4 competitive inhibitor Control: Hill Equation – positive 
cooperativity 
BSA: Hill Equation – positive 
cooperativity 
Codeine3 competitive inhibitor 
(Vmax decreased with 
BSA) 
Control: Sigmoidal kinetics 
BSA: Sigmoidal kinetics (amplified) 
1(Rowland et al., 2008);  2(Uchaipichat et al., 2006);  3(Raungrut et al., 2010);  4(Rowland et al., 2006) 
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1.4.2 Physiological function of albumin 
Albumin is the most abundant plasma protein in humans and other 
mammalians (Peters, 1996). Around 3.5 – 5.0 g/dl are present in the human 
plasma (Ganong, 1989). Its functions include maintaining the oncotic pressure, 
buffering pH and transporting endogenous compounds such as metals, ions, 
fatty acids, amino acids, bilirubin, enzymes, thyroid and steroid hormones, and 
exogenous compounds including drugs, environmental chemicals and dietary 
fatty acids. Binding to albumin keeps the substances from being rapidly filtered 
through the glomeruli and provides a stable reservoir. It is also preventing the 
occurrence of high local concentrations of compounds and therefore reducing 
the risk of intoxications.  
 
1.4.3 Fatty acids 
Esterified long chain fatty acids are the main components of the phospholipid 
membranes. Short- and medium-chain fatty acids are generally not esterified 
and bound to albumin, or other lipid binding proteins. The binding to albumin 
can reach from 3 to 30 molecules of fatty acids per molecule of albumin, 
depending on the concentrations in the plasma (Guyton and Hall, 2006). Fatty 
acids can be used as a source for energy. They can also act as second 
messenger within cells for the transduction of external signals. Their most 
important function is, however, to serve as precursors for biologically active 
signaling molecules, called eicosanoids. These compounds include 
hydroxyeicosatetraenes, prostanoids (prostaglandins, prostacyclins and 
tromboxanes), leukotrienes, resolvins and isoprostanes (Ware and Bruckner 
1992) 
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1.5 Aglycone UGT Substrates Used in the Study  
1.5.1 4-Methylumbelliferone 
 
OO
CH3
O
Gluc
 
Figure 8. 4-Methylumbelliferone glucuronide 
 
4-Methylumbelliferone (4MU) is a coumarin derivate, often used for in vitro 
studies of UGT enzymes, as it is glucuronidated by a wide range of isoforms, 
such as UGT1A1, 1A3, 1A6, 1A7, 1A9, 1A10, 2B7 and 2B15 (Ismail et al., 
2010). Despite the wide use of coumarin derivatives for their antimicrobial and, 
more important, anticoagulative proprieties, 4MU has no pharmacological 
relevance. 
 
1.5.2 Entacapone 
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O
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O
O2N
Gluc
 
Figure 9. Entacapone glucuronide 
 
Entacapone is a synthetic drug used in combination with levodopa to treat 
Parkinson’s disease. Its effect is based on the inhibition of the catechol-O-
methyl transferase (COMT) and therefore reducing its ability to inactivate 
levodopa and dopamine. 
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Entacapone is glucuronidated, at very different rates, by UGTs 1A1, 1A3, 1A4, 
1A6, 1A7, 1A8, 1A9 and 1A10 (Luukkanen et al., 2005). In the human liver, it is 
almost exclusively metabolized by UGT1A9. Polymorphism of UGT1A9 can 
induce hepatic dysfunctions (Martignoni et al., 2005), when Entacapone is 
administrated regularly. An epidemiologic study is still needed to confirm this 
polymorphism effect, however.  
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2 Aims and significance 
 
As described above in section 1.4, there is a relevant need to improve in vitro 
experiments for UGTs. The addition of BSA was shown to be an important help 
to achieve this goal, but not all the isoforms present in the human body have 
been tested yet (Table 2). It is also noteworthy that all the published data until 
now are from a single laboratory, and they have used recombinant UGTs and 
liver microsomes that were prepared in their lab and, therefore, are not (easily) 
available for other researchers (Rowland et al., 2008;  Uchaipichat et al., 2006;  
Raungrut et al., 2010;  Rowland et al., 2006). 
 
Our objectives were to analyze the effect of albumin on our recombinant UGTs, 
expressed in baculovirus-infected Sf9 insect cells, and to compare it with 
commercial available human liver microsomes (HLM) and human intestinal 
microsomes (HIM). Moreover, the effect of BSA addition on the glucuronidation 
of 4MU by recombinant UGT 1A9 has already been published, meaning that 
our results could be compared to their (Rowland et al., 2008a).  
 
We have decided to use 4-methylumbeliferone and entacapone as substrates 
since they are known to be metabolized by a broader range of isoforms. 
 
This thesis provides important new knowledge on the effect of BSA on an 
unexplored group of recombinant UGTs. The acquired information can be a 
significant help in the future for improving in vitro experiments and better 
understanding of the mechanisms of UGT enzymes activity. 
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3 Materials and Methods 
3.1 Materials 
Magnesium chloride hexahydrate and perchloric acid were obtained from 
Merck (Darmstadt, Germany). Formic acid (98–100%) was obtained from 
Riedel-de Haeën (Seelze, Germany). Methanol, Acetonitrile, Glycerol, 
Alamethicin (from Trichoderma Viride), UDPGA (triammonium salt, 98–100%, 
CAS number 63700-19-6), Bovine Serum Albumin (Essentially fatty acid free, 
CAS number 9048-46-8), 4-Methylumbeliferone (4MU; CAS number 90-33-5) 
and 4MU-glucuronide (CAS number 6160-80-1)where all purchased from 
Sigma-Aldrich (St.Louis, MO, USA). Entacapone was obtained from 
OrionPharma (Espoo, Finland) and the Entacapone glucuronide was 
synthesized in our laboratory. High performance liquid chromatography 
(HPLC)-grade solvents were used throughout the study. 
 
3.2 Enzyme sources 
Recombinant human UGTs were expressed as Histagged proteins in 
baculovirus-infected Sf9 insect cells as described previously (Kurkela et al., 
2007; Sneitz et al., 2009 and references therein). The relative expression level 
of each recombinant UGT isoform was immunodetected using tetra-His 
antibodies (QIAGEN, Hilden, Germany) as described earlier (Kurkela et al., 
2007). Protein concentrations were determined by the BCA method (Pierce 
Biotechnology, Rockford, IL). Pooled human liver microsomes [HLM (lot 
18888)] and human intestinal microsomes [HIM (lot 28095)] were purchased 
from BD Gentest (Woburn, MA, USA). 
 
 
3.3 Binding assay for BSA 
For the detection of the binding of 4MU and Entacapone to BSA we have used 
Amicon Ultra Centrifugal Filters (0.5mL, Ultracel – 10K Membrane) from 
Millipore (Carrigtwohill, Co. Cork, Ireland). 
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3.3.1 Unspecific binding of 4MU to the filter membrane 
The pretreatment consisted of filtering 500µl milliQ water, 50 mM phosphate 
buffer pH 7.4, 1µM 4MU, 10µM 4MU, Tween 20, Tween 80 or benzalkonium 
chloride (BAK) in order to impregnate the filters. The pretreated filters and the 
control (not pretreated) were tested using 10, 100 and 1,000µM of 4MU (Table 
6 and Table 7). Two or three filtrates per sample with volumes of either 50 or 
100µl were collected to analyze the 4MU concentration by HPLC (see section 
3.6). The unspecific binding was calculated comparing the concentration of 
4MU in the filtrate to the one in the reservoir. 
 
3.3.2 Binding assay of 4MU 
Solutions of 4MU within the concentration range of 2 - 160µM, in 50 mM 
phosphate buffer pH 7.4, were incubated in presence of 0.1% BSA at 37°C for 
60 min. From each test solution, 450µL were transferred into the reservoir of an 
Ultra Centrifugal Filter, previously pretreated with TW 20 (see section 4.1.1), 
and centrifuged for 0.5min at 5’000g. The feed and the filtrate were collected 
and ice cold perchloric acid was added to precipitate the BSA. The tubes were 
transferred on ice for approximately 20 min and then centrifuged for 10 min at 
16.000 x g. The supernatant in the tubes was collected and used for the 
analysis by HPLC (see section 3.6). Controls were performed in absence of 
BSA. Two different formulas were used to evaluate the fu: 
 
a) Filtrate of the control / Filtrate of the test tubes 
b) Feed of the test tubes / Filtrate of the test tubes 
 
Given by the unfinished results, the fu for 4MU used in this thesis are taken 
from (Rowland et al., 2008). Binding data for Entacapone are not available in 
the literature, yet. The data displayed in the kinetics of Entacapone is, 
therefore, not corrected for binding and due to this, the Km values are to be 
lower in presence of BSA. The Vmax values, in any case, should represent the 
correct value since it is expected to be independent of the exact substrate 
concentration in the solution, even if it might appear to be reached at higher 
substrate concentrations in the presence of BSA. 
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3.4 “Washing” of UGT1A7-containing membranes with 1% BSA 
Recombinant UGT1A7 membranes were pretreated with 1% BSA in phosphate 
buffer for 30 min, either on ice or at 37°C. The co ntrol samples for this 
experiment were incubated with phosphate buffer without BSA at the 
corresponding temperatures. 
 
The effect of washing was determined by comparing the enzymes pretreated 
with 1% BSA to the corresponding control. A second set of controls was 
prepared by adding 0.1% BSA to the reaction mixture of the first controls. The 
enzymes were incubated in presence of 400µM Entacapone according to 
section 3.5 and the formed Entacapone glucuronide was analyzed as described 
in section 3.6. 
 
3.5 Incubation conditions for recombinant UGTs, HLM and HIM 
with 4MU and Entacapone 
The substrates were dissolved and diluted in pure methanol to obtain the 
desired concentrations. The different dilutions were added into Eppendorf tubes 
and centrifuged under vacuum conditions to evaporate the methanol. 90 µL of 
reaction mixture, containing 50 mM phosphate buffer pH 7.4, magnesium 
chloride, UGT enzymes at different concentrations (Table 3, Table 4 and Table 
5) and when needed 0.05% to 2% of BSA, was added to the tubes. The mixture 
for HLM and HIM contained in addition alamethicin at a final concentration of 
5% of the microsomal protein concentrations. After the total dissolution of 
substrate (approximately 20 min), the tubes were transferred into a heating 
block at a temperature of 37°C for a pre-incubation  of 5 min. 10 µL of the 
appropriate dilution of UDPGA was then added to the mixture to start the 
reaction and 10µL of ice cold perchloric acid were used to stop it after the 
incubation time, as listed in Table 3-5. The stopped solutions where put on ice 
for approximately 20 min and then centrifuged then for 10 min at 16,000 x g. 
The supernatants were collected and subjected to the respective liquid 
chromatography analysis (see section 3.6). 
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Table 4 and Table 5 show different incubation conditions for the 4MU and 
Entacapone kinetics and their respective UDPGA kinetics. The protein 
concentrations and incubation times for the kinetic analyses reactions were 
selected based on preliminary assays to ensure that product formation was 
within the linear range with respect to protein concentration and incubation 
time, and that the substrate consumption was less than 10%. The substrate 
concentrations for the 4MU and Entacapone screenings were close to the Km 
values that were earlier measured in our lab, or reported in the publication of 
Luukkanen et al., 2005, respectively. All the concentration points were tested in 
triplicates, except the preliminary tests, where the values represent the average 
of two measurements. 
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Table 3. The incubation conditions for the screenings of recombinant UGTs, HLM and 
HIM with 4MU and Entacapone as the aglycone substrates 
 Incubation time 
(min) 
Amount of enzyme 
(µg) 
Substrate concentration 
(µM) 
4MU 
   
1A1 20 10 50 
1A3 20 25 20 
1A6 20 10 20 
1A7 20 3 25 
1A8 20 25 200 
1A9 20 10 20 
1A10 20 10 25 
2A1 20 10 50 
2A2 20 10 50 
2B4 20 50 100 
2B7 20 25 100 
2B15 20 10 50 
2B15 (comm) 20 10 50 
HLM 20 5 50 
HIM 20 5 50 
Entacapone 
   
1A1 60 10 100 
1A3 60 10 200 
1A7 10 2 10 
1A8 60 10 50 
1A9 10 2 10 
1A10 60 10 50 
2A1 60 5 50 
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Table 4. The incubation conditions for the enzyme kinetics of recombinant UGTs and 
HLM with 4MU; 4MU kinetic analyses were performed in the presence of 5 mM 
UDPGA; the kinetics of UDPGA were carried out in the presence of 50 µM 4MU for 
UTG 1A9,  or 20 µM 4MU for UGTs 1A7 and 2A1. 
 Incubation time 
(min) 
Amount of enzyme 
(µg) 
Substrate concentration 
range (µM)/ amount of 
different concentrations 
4MU kinetics 
   
1A7 20 2 10 - 750/ 8 
1A9 20 2 10 – 750/ 8 
1A10 20 2 5 – 800/ 10 
2A1 20 2 5 – 500/ 8 
2B15 20 2 10 – 1000/ 10 
HLM 10 2 10 – 1000/ 10 
UDPGA kinetics 
   
1A7 20 2 50 – 5000/ 8 
1A9 20 2 50 – 5000/ 8 
2A1 20 2 50 – 5000/ 8 
 
 
Table 5. Incubation conditions for the enzyme kinetics of recombinant UGTs, HLM and 
HIM with Entacapone; Entacapone kinetics were performed in the presence of 5 mM of 
UDPGA; the kinetics of UDPGA were carried out with either 75 µM Entacapone 
(UTG1A9) or 500µM Entacapone (UGTs 1A7, 1A8 and 1A10). 
 Incubation time 
(min) 
Amount of enzyme 
(µg) 
Substrate concentration 
range (µM)/ amount of 
different concentrations 
Entacapone 
kinetics 
   
1A7 10 2 5 - 750/ 10 
1A8 60 3 10 – 600/ 8 
1A9 10 2 5 – 750/ 10 
1A10 60 10 10 – 500/ 8 
HLM 15 2 10 – 750/ 10 
HIM 60 5 10 – 750/ 8 
UDPGA kinetics 
   
1A7 10 2 50 – 5000/ 8 
1A8 60 3 500 – 5000/ 8 
1A9 10 2 50 – 5000/ 8 
1A10 60 7 50 – 5000/ 8 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
 
31 
3.6 Analytical methods 
The concentration of 4MU D-glucuronide was analyzed with an HPLC system 
consisting of the Agilent 1100 series degasser, binary pump, autosampler, 
thermostated column compartment, multiple wavelength UV detector, and 
fluorescence detector (Agilent Technologies, Palo Alto, CA). The resulting 
chromatograms were analyzed with Agilent ChemStation software (revision 
B.01.01) on Windows 2000 Professional workstation. The column used for this 
instrument was the Chromolith SpeedROD, RP-18e (50×4.6 mm; Merck) and 
the column temperature was 40°C. The mobile phase c onsisted of 80% 50 mM 
Phosphate Buffer, pH 3.0 (A) and 20% methanol (B) and a flow rate of 2 
ml/min, were kept constant during the entire run that was stopped after 10 min. 
The retention time of the 4MU glucuronide was 1.5 min. The detection was 
performed using fluorescence detection with excitation at 316 nm and emission 
at 382 nm. 
 
The formation of Entacapone D-glucuronide was determined using the UPLC 
system Waters Acquity UPLC (Waters, Milford, MA), equipped with column 
manager, sample manager, binary solvent pump, and photodiode array UV 
detector. The resulting chromatograms were analyzed with Empower 2 
software (Build 2154; Waters) on Windows XP Professional. The UPLC column 
was Acquity UPLC BEH C18 (1.7 µm, 2.1×100 mm; Waters), equipped with a 
precolumn, and the column temperature was 40°C. The  mobile phase 
consisted of 0.1% formic acid (A) and acetonitrile (B), and the flow rate was 0.5 
ml/min throughout. UV absorbance at 309 nm was used for detection. The 
gradient in this method was as follows: 0 to 3 min of 20% B; 3 to 3.20 min of 
30% B; 3.20 to 4.10 min of 80% B; and 4.10 to 6 min of 20% B. The 
Entacapone glucuronide retention time was 2.2 min. 
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3.7 Enzyme kinetic analysis 
Kinetic analyses were performed using the GraphPad Prism program, version 
5.01 for Windows (Graph- Pad Software Inc., San Diego, CA). The best model 
was selected based on the corrected Akaike’s information criterion (AICc), the 
calculated r2 values, residuals graph, parameter S.E. estimates, 95% 
confidence intervals, and visual inspection of Eadie-Hofstee plots. Data were 
fitted with the following models: 
1. Michaelis Menten equation 
ν=
V
max
[S]
K
m
+ [S ]
 
where v is the initial velocity of the enzyme reaction, Vmax is the maximum 
velocity, [S] is the substrate concentration, and Km is the velocity at 0.5 of Vmax. 
2. Substrate inhibition model equation 
ν=
V
max
[S]
K
m
+[S](1 + [S ]
K i
)
 
where Ki is the descriptor for the inhibitory effect of the substrate. 
 
Various equations were used to describe the two-site kinetic models. Equations 
no. 3 and 4 were applied for kinetics where the substrate seemed to act as 
noncompetitive/mixed type inhibitor. 
3. Two site model equation I (Galetin et al., 2002; Zhou et al., 2010) 
v=
V
max
( [S ]
KS
+
b [S ]2
K S
2 )
1 + [S]
KS
+
[S]2
KS
2
 
where b is the constant that affects the product formation and Ks is the affinity 
constant for the binding of the substrate. 
4. Two site inhibition model equation II (Houston and Kenworthy, 2000) 
v=
V
max
( [S]
KS
+
b[S ]2
aK
s
2 )
1 + 2[S]
KS
+
[S ]2
aKS
2
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where a is the constant that effects the affinity of the substrate to the enzyme. 
 
For the two-site kinetic models, where autoactivation occurred, data were fitted 
to the allosteric model equation: 
5. Allosteric sigmoidal model (Hill equation) 
v=
V
max
[S]h
[S]50h + [S]h
 
where S50 is the velocity at 0.5 Vmax and h is the Hill coefficient. 
 
As already mentioned, it is not possible to perform exact comparisons between 
atypical kinetics according to the Km value, and the parameter Vmax should also 
be used carefully in such comparisons. 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
 
34 
4 Results 
4.1 Preliminary Tests 
Preliminary tests where needed to establish a standardized method for 
following the kinetics of different glucuronidation reactions in which different 
substrates and different UGT isoforms were examined. Tests that were 
previously performed by others in our laboratory are not reported in this thesis. 
4.1.1 Unspecific binding of 4MU to Ultra Centrifugal Filters 
4.1.1.1 Pretreatments with water, buffer and 4MU 
The filter seemed to bind 4MU at saturating concentrations. After several 
rounds of filtrations, higher concentrations of substrates were present in the 
filtrate (Table 6). At higher initial concentrations of substrate, lower percentages 
of loss occurred. Although only tested with 100 µM 4MU, the pretreatment with 
50 mM phosphate buffer pH 7.4 seemed to decrease nonspecific binding. 
There were no statistically significant differences, however, between the filters 
washed with water and the filters washed with phosphate buffer. 
 
The pretreatment with 4MU lowered the unspecific binding of the filters 
compared to the other pretreatments. Nevertheless, there were no differences 
between the 50 and 100 µM of 4MU. 
4.1.1.2 Pretreatments with Tween 20, Tween 80 and BAK 
The mild detergents Tween 20 and Tween 80 lowered the unspecific binding of 
the filter compared to the control (Table 6 and Table 7), and BAK further 
enhanced this effect. When 100 µl of pre-filtrate (filtrate 1) were removed, the 
concentration of 4MU in the filtrate (filtrate 2) was the same as in the reservoir. 
 
A second test revealed that the pretreatment with Tween 20 also eliminated the 
unspecific substrate binding to the filter when 50µl of pre-filtrate were removed 
(Table 7). 
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Table 6. Test for the pretreatment of the Ultra Centrifugal filters I; the volume of each 
filtrate was approximately 50µl 
Concentration 
of 4MU 
Solution for 
pretreatment 
Fraction unbound, fu 
Filtrate 1 Filtrate 2 Filtrate 3 
10µM No pretreatment N.A. N.A. 0.78 
mQ water 0.12 0.58 0.74 
50mM PB 0.13 0.59 0.76 
100µM No pretreatment 0.11 0.61 0.76 
50mM PB 0.17 0.65 0.87 
 1µM 4MU 0.20 0.77 0.93 
 10µM 4MU 0.26 0.78 0.93 
1000µM No pretreatment N.A. N.A. N.A. 
Pretreated with mQ water 0.44 0.97 N.A. 
Pretreated with 50mM PB 0.49 0.92 N.A. 
 
Table 7. Test for the pretreatment of the Ultra Centrifugal filters II; the fu are evaluated 
for a 4MU concentration of 100µM 
Solution for 
pretreatment 
Fraction unbound, fu 
Filtrate 1 Filtrate 2 Filtrate 3 
100µl of filtrate 
   
TW 20 0.86 1.01 N.A. 
TW 80 0.87 1.01 N.A. 
BAK 0.10 0.70 N.A. 
50µl of filtrate 
 
 
 
TW 20 N.A. 0.98 
 
1.00 
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4.1.2 Binding assay for 0.1% BSA 
The binding of 4MU to BSA was linear in the range between 2 and 160µM of 
substrate (Figure 10). Even if the retained phase (feed) containing albumin was 
pretreated with PCA, the release of the substrate was not complete. Compared 
to the control, BSA was still retaining around 10% of 4MU. The fu of the 
substrate in the filtrate increased from 0.7 to 0.81 of the controls filtrate or the 
concentration in the feed, respectively. 
 
Since the binding experiments were incomplete at the time of writing this thesis, 
the fu value for 4MU that was used in the kinetic analyses was taken from the 
publication of (Rowland et al., 2006), namely fu values of 0.89, 0.49 and 0.27 in 
the presence of  0.1, 1 and 2% BSA, respectively. The data for Entacapone 
were not corrected for binding since no such data is available, although it surely 
binds to BSA, perhaps even to a higher degree than 4MU. Nevertheless, in the 
absence of determined binding values, the kinetic constantans are given in this 
thesis as if the fu value is 1.0, but I would lie to stress that this is temporary and 
the real fu value or values, after determining Entacapone binding to BSA, will 
probably be smaller, leading to smaller Km/Ks values, too. 
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Figure 10. Unbound fractions of different concentrations of 4MU in presence of 
0.1% BSA
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4.1.3 “Washing” membranes with 1% BSA 
Contrary to hope and expectations, treatment of insect cell membranes that 
contain recombinant UGT1A7 with 1% BSA prior to the glucuronidation reaction 
incubation did not increase the glucuronidation rate. The effect of BSA was only 
visible when it was present in the mixture during the reaction (Figure 11, 
“Washed control + 0.1% BSA”). The assay was performed with Entacapone as 
the aglycone substrate. 
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Figure 11. Washing test of UGT1A7 with Entacapone as the aglicone substrate 
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4.1.4 Influence of glycerol and incubation temperature on UGT2A1 
activity 
The test was performed on UGT2A1 with 4MU as the substrate. The addition of 
glycerol to the reaction mixture lowered slightly the activity of UGT2A1 (Figure 
12). This decrease was also visible when glycerol was added in combination 
with 0.1% BSA. In the same set of incubations we have also tested the effect of 
incubation temperature on activity and the results show that body temperature, 
37°C, is better than room temperature, 23°C (Figure  12).  
 
 
 
 
 
Figure 12. Influence of incubation temperature, 2% glycerol, and 0.1% BSA on 
4MU (50 µM) glucuronidation by UGT2A1 (0.02 mg/ml) 
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4.1.5 Linearity of the reaction with respect to time with human intestinal 
microsomes 
The glucuronidation of Entacapone by the commercial HIM was largely linear 
with respect to incubation time within the time range of 16 and 56 min, both in 
the absence and the presence of 0.1% BSA. A slight decrease of activity is, 
however, visible after 56 min in the sample without BSA (Figure 13). 
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Figure 13. Preliminary test for the linearity with time of HIM (5 µg) with Entacapone 
(500 µM) as the aglycone substrate. 
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4.1.6 Linearity of the glucuronidation rate with respect to enzyme 
concentration and selection of BSA concentration 
The results showed that the effects of 0.1% BSA and 1% BSA were similar 
when the enzyme concentration, UGT2A1-containing membranes in this case, 
was between 2 and 50µg of UGT2A1, and that the glucuronidation rate, 
calculated per mg (total) membrane protein was essentially the same for all the 
tested concentrations (Figure 14). The BSA concentration of 0.05% stimulated 
the activity of the enzyme like higher BSA concentrations only up to 20µg of 
UGT2A1. At higher enzyme concentrations, like 50 µg, 0.05% BSA seemed to 
be too low for a proper activation (Figure 14). The concentration of 0.1% BSA 
was therefore used through all the experiments. Other concentrations were 
anyway still tested in other experiments to analyze the variability between 
different systems. 
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Figure 14. Glucuronidation of 4MU (50µM) by UGT2A1 in presence of 0.05%, 
0.1%, 1% BSA 
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4.1.7 4MU screening 
We have assayed all the human UGTs for the glucuronidation rate of 4MU, with 
and without BSA. The highest 4MU glucuronidation rates were found with 
UGTs 1A7, 1A9, 1A10, 2A1 and 2B15 (Figure 15). Very low rates were found 
for UGTs 1A1, 1A3, 1A6, 1A8, 2A2 and 2B7. The activation of the enzymes by 
the addition of 2% BSA was observed in almost all the isoforms, with the 
exception of UGT1A8 and UGT2B7, where the albumin seemed even to lower 
the activity. The human liver and intestine microsomes (HLM and HIM, 
respectively) and the commercially available recombinant UGT2B15, also 
showed an increased activity in presence of BSA. The data of 2% BSA are 
corrected for substrate binding, by using the data of (Rowland et al., 2007). 
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Figure 15. Screening of UGT selectivity towards 4MU 
The substrate concentrations used were different for different isoforms, as described in 
Table 3. The commercial UGT2B15 has no His-tag and, therefore, its glucuronidation 
rate could not be normalized for expression level. The same holds for the different 
UGTs in HLM and HIM. 
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4.1.8 Entacapone screening 
The main UGTs responsible for the glucuronidation of Entacapone were found 
to be 1A7, 1A8, 1A9, 1A10, whereas UGTs 1A1, 1A3, and 2A1 showed a 
minimal or almost no activity (Figure 16). The activity of all the tested isoforms 
increased in presence of 0.1% BSA. Data for the BSA concentration of 0.05% 
are only available for the UGTs 1A8, 1A9, 1A10 and 2A1. The visible increase 
of the activity in the presence of 0.05% compared to 0.1% BSA is given by the 
lower binding of the substrate to BSA. Comparisons between the two 
concentrations might, therefore, be misleading at this stage. It is anticipated 
that once the exact degree of substrate binding to each concentration of BSA 
(to be achieved soon), the effect on activity will be similar. An increase of 
activity compared to the control was however significant for both. 
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Figure 16. Screening of UGTs activity towards Entacapone 
The substrate concentrations used are different in each isoform (Table 3). It is not 
possible to accomplish direct comparisons between the different isoforms. 
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4.2 Enzyme kinetics 
4.2.1 4- Methylumbeliferone 
4.2.1.1 Substrate kinetics 
Based on the AICc and the r2 values, the two-site model equations were found 
to best describe the 4MU kinetics of UGTs 1A7, 1A9, 1A10, 2A1 and 2B15 in 
presence of BSA. The controls (no added BSA) for these isoforms were not 
clearly demonstrating a two-site model, but for better comparisons between the 
kinetics, the two-site model equations were used to fit all the kinetics. The two-
site model equation I was , therefore, used to fit the kinetics of the UGTs 1A7 
and 2B15, whereas equation II was used for the UGTs 1A9, 1A10 and 2A1. 
 
All the isoforms mentioned increased or even unmasked the evidence of the 
presence of a second binding site for 4MU when BSA was added. A look to the 
graphs where the rate of product formation was plotted versus the 
concentration of substrate, it seemed that 4MU was exhibiting a partial 
inhibition of the enzyme (Figure 17). A two site model autoactivation, however, 
was not visible in the Eadie- Hofstee plots for any isoform (Figure 18) 
 
The addition of BSA to the samples increased Vmax by 2 to 5 fold in all the 
isoforms. Given by the presence of atypical kinetics, a comparison of the Ks (all 
data reported in Table 8) will not be very meaningful. 
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Figure 17. Kinetics of 4MU glucuronidation in the presence of different BSA 
concentrations  
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Figure 18. Eadie-Hofstee plots of 4MU kinetics 
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Table 8. Parameters of the substrate kinetics with 4MU as the main substrate 
Parameter control Concentration of BSA 
0.05% 0.1% 1% 2% 
1A71      
Vmax 0.269 ± 0.03 1.138 ± 0.02 1.203 ± 0.04 1.262 ± 0.01 N.A. 
KS 41.0 ± 6.5 45.36 ± 1.1 42.74 ± 1.2 49.13 ± 2.8 N.A. 
b 0.421 ± 0.06 0.119 ± 0.01 0.1302 ± 0.01 0.169 ± 0.02 N.A. 
1A92      
Vmax 1.44 ± 0.08 2.902 ± 0.13 3.041 ± 0.21 4.148 ± 0.22 N.A. 
Ks 26.74 ± 4.06 12.31 ± 1.67 11.34 ± 2.39 25.73  ± 2.63 N.A. 
a 7.474 ± 5.44 5.109 ± 1.51 7.08 ± 3.49 2.667 ± 0.89 N.A. 
b 0.156 ± 0.06 0.109 ± 0.01 0.073 ± 0.02 0.006 ± 0.03 N.A. 
1A102       
Vmax 16.28 ± 0.95 N.A. 22.52 ± 1.27 29.71 ± 3.02 N.A. 
Ks 179.9 ± 20.0 N.A. 92.67 ± 8.47 173.1 ± 26.85 N.A. 
a 0.847 ± 0.66 N.A. 0.517 ± 0.15 0.181 ± 0.09 N.A. 
b 0.296 ± 0.049 N.A. 0.162 ± 0.007 0.160 ± 0.015 N.A. 
2A12      
Vmax 2.172 ± 0.059 4.863 ± 0.547 5.106 ± 0.150 5.358 ± 0.272 5.83 ± 0.208 
Ks 7.375 ± 39.30 9.277 ± 3.78 11.01 ± 0.93 11.37 ± 1.36 11.68 ± 0.95 
a N.A. 6.468 ± 9.627 3.169 ± 1.29 2.686 ± 1.77 2.663 ± 1.533 
b N.A. 0.276 ± 0.046 0.352 ± 0.010 0.300 ± 0.018 0.259 ± 0.031 
2B151      
Vmax 1.001 ± 0.460 N.A. 3.046 ± 0.085 4.394 ± 0.089 N.A. 
Ks 30.57 ± 11.65 N.A. 42.47 ± 2.42 75.22 ± 2.36 N.A. 
b 1.241 ± 0.598 N.A. 0.374 ± 0.019 0.267 ± 0.013 N.A. 
HLM3      
Vmax 13.58 ± 0,24 N.A. 11.6 ± 0,11 11.83 ± 0,193 N.A. 
Km 42.4 ± 3,8 N.A. 18.5 ± 1,06 25.91 ± 1,77 N.A. 
1
 Two-site model equation I; 2 Two site model equation II; 3 Michaelis Menten equation 
 
 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
 
47 
4.2.1.2 Substrate kinetics for human liver microsomes 
Although HLMs contain a mixture of different 4MU glucuronidating UGT 
isoforms, the curves of the performed kinetics appeared linear in the Eadie- 
Hofstee plot (Figure 18). The Michaelis-Menten equation was therefore used to 
give an approximate estimation of the parameters (Table 8). The addition of 0.1 
and 1% BSA to the incubation mixture seemed to slightly lower both the Vmax 
and the Km. 
 
4.2.1.3 UDPGA kinetics 
The kinetic analyses with respect to UDPGA, using 4MU as the aglycone 
substrate, are shown in Fig. 18. The analyses for UGTs 1A7 and 1A9 were 
consistent with the Michaelis-Menten model, while UGT2A1 presented a 
biphasic model with respect to UDPGA. The addition of BSA seemed to lower 
the biphasic effect in the latter enzyme. Due to this, the Michaelis Menten 
equation was also used to fit the kinetics of UGT2A1. 
 
As shown in Table 9, the Vmax was increased while Km decreased in all the 
isoforms, when 0.1% BSA was added to the incubation mixture. 
 
Table 9. Parameter for the UDPGA kinetics with 4MU as the aglycone substrate; the 
parameter are evaluated by fitting the Michaelis Menten equation to the kinetics 
Parameter control 0.1% BSA 
1A7   
Vmax (nmol/min/mg) 0.207± 0.008 0.450 ±0.008 
Km (µM) 906.2 ± 86.11 750.2 ±36.83 
1A9   
Vmax (nmol/min/mg) 0.477 ±0.0133 0.946 ±0.018 
Km (µM) 180.1 ±21.62 104.5 ±9.85 
2A1   
Vmax (nmol/min/mg) 0.64 1 ±0.020 2.225 ±0.031 
Km (µg) 285.5 ±33.78 75.75 ±5.66 
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Figure 19. UDPGA kinetics for the glucuronidation of 4MU 
 
 
 
 
 
 
 
 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
 
49 
4.2.2 Entacapone 
4.2.2.1 Substrate kinetics 
The kinetics of Entacapone glucuronidation were analyzed for UGTs 1A7 - 
1A10, as well as for HIM and HLM (Figure 20). Eadie-Hofstee plots of the 
results for UGTs 1A7- 1A10 (Figure 21) suggest atypical kinetics both in the 
absence and the presence of BSA for most of these UGTs. UGT1A7 was the 
only enzyme that was linear in the Eadie-Hofstee plot and was best described 
by the Michaelis-Menten equation. Inhibition by the substrate was visible in 
UGT1A9, whereas the substrate inhibition model and the two-site model no. I 
were consistent with the control and the kinetics in presence of BSA for this 
enzyme, respectively. Comparisons between latter two kinetics were 
accomplished by using the two-site model equation I for both. In UGT1A10, the 
addition of BSA increased the already present autoactivation. The Hill equation 
was, therefore, applied for these kinetics. 
 
The description of the kinetics of the UGT1A8 turned out to be more 
complicated, given by the three phases visible in the Eadie-Hofstee plot. The 
enzyme exhibited autoactivation at lower concentrations of Entacapone, but 
substrate inhibition at higher concentrations. According to the AICc, the 
substrate inhibition equation and the two-site model equation II were best 
describing the control and the kinetics of UGT1A8 in the presence of BSA, 
respectively. Due to the difficulty to compare between these two kinetics, the 
concentrations in the range of inhibition were excluded and the Hill equation 
was fitted for both. In this case, the autoactivation was considered and the S50 
values could be used to determine the inhibition pattern present in absence of 
BSA. 
 
The Vmax of the UGTs 1A8, 1A9 and 1A10 were 2-3 fold higher in presence of 
BSA than in its absence. Moreover, the Vmax increase in UGT1A7 was even 7 
fold. In presence of BSA Km or Ks increased in UGTs 1A7 and 1A9, 
respectively. In contrast, the S50 decreased in UGTs 1A8 and 1A1 
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Figure 20. Kinetics of Entacapone in presence or absence of BSA 
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Figure 21. Eadie-Hofstee plots of Entacapone kinetics 
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Table 10. Parameters of the substrate kinetics with Entacapone as the aglycone 
substrate  
Parameter control 0.1% BSA Used equation 
1A7   
Michaelis Menten Vmax 0.119 ± 0.119 0.794 ± 0.800 
Km 45.73 ± 45.73 65.93 ± 68.55 
1A8   
Hill equation 
Vmax 0.156 ± 0.0166 0.282 ± 0.005 
S50 117.4 ± 22.25 45.66 ± 1.517 
h 0.964 ± 0.132 1.68 ± 0.053 
1A9   
Two-site model 
equation I 
Vmax 10.85 ±1.001 29.58 ±1.684 
Ks 36.6 ± 4.640 45.01 ± 3.976 
b 0.488 ± 0.064 0.3756 ± 0.036 
1A10   
Hill equation 
Vmax 0.933 ± 0.026 2.708 ± 0.018 
S50 59.76 ± 4.585 36.14 ± 0.5812 
h 0.954 ± 0.051 1.587 ± 0.041 
HIM   
Michaelis Menten Vmax 0.094 ± 0.005 0.990 ± 0.035 
Km 23.6 ± 4.633 52.53 ± 5.628 
HLM   
Two-site model 
equation I 
Vmax 7.757 ± 1.504 24.29 ± 1.300 
Ks 34.75 ± 8.341 30.41 ± 2.736 
b 0.677 ± 0.164 0.378 ± 0.034 
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4.2.2.2 Entacapone glucuronidation kinetics of HLM and HIM 
The kinetics of HLM in the absence of BSA were best described by the 
substrate inhibition model, whereas the addition of BSA revealed a two-site 
model. Entacapone seemed to act as a partial inhibitor by attaching a second 
binding site. The two site model equation I was, therefore, used to evaluate the 
parameters of both kinetics. 
 
Given the presence of different isoforms in HIM, it was difficult to find an 
appropriate equation for its kinetics. The simple Michaelis-Menten equation 
was fitted to the control and to the kinetics in presence of BSA to give an 
approximate estimation of the changes in Vmax. 
 
BSA increased significantly the Vmax of both microsomes. Comparisons 
between the Ks and in this case also the Km are not meaningful (Table 10). 
 
4.2.2.3 UDPGA Kinetics in Entacapone glucuronidation 
The evaluation of the results of the UDPGA kinetics with Entacapone as the 
aglycone substrate (Figure 22) showed a decrease in activity at higher 
concentrations of UDPGA in most cases. Only UGT1A9 in the presence of 
BSA, and the UGT1A10 control did not exhibit any inhibition by UDPGA below 
5mM. The substrate inhibition equation was fitted for all the kinetics, namely 
with UGTs 1A7 - 1A10. 
 
The addition of BSA to the incubation mixture increased the Vmax of all the 
isoforms and the Km of UGTs 1A7 and 1A8. The Km of UGTs 1A9 and 1A10, 
however, were decreased in the presence of BSA (Table 11). 
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Table 11. Kinetic parameter for UDPGA kinetics with Entacapone as the main 
substrate; the parameters were evaluated by fitting the substrate inhibition equation to 
the kinetics 
Parameter control 0.1% BSA 
1A7   
Vmax (nmol/min/mg) 0.3306 ±0.02816 1.389 ±0.09792 
Km (µM) 781.9 ±115.5 1’884 ±189.1 
Ki (µM) 5’690 ±1169 11’145 ±2’406 
1A8   
Vmax (nmol/min/mg) 0.1221 ±0.01444 0.3026 ±0.02236 
Km (µM) 1’180 ±237.8 1’680 ±195.4 
Ki (µM) 8’133 ±2’599 22’851 ±8’974 
1A9   
Vmax (nmol/min/mg) 2.605 ±0.1223 5.359 ±0.07346 
Km (µM) 416.0 ±43.24 247.4 ±13.22 
Ki (µM) 13’556 ±2’852 N.A. 
1A10   
Vmax (nmol/min/mg) 0.3 ±0.003468 1.534 ±0.05616 
Km (µM) 704.2 ±22.67 592.0 ±43.06 
Ki (µM) N.A. 15’044 ±2’445 
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Figure 22. UDPGA kinetics for the glucuronidation of Entacapone 
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5 Discussion 
5.1 Preliminary assays 
5.1.1 Unspecific binding to the filter membrane 
It was previously reported that the nonspecific binding of the neutral substance 
4MU to the filter membrane decreases, when the filter is pretreated with Tween 
80 (Lee et al 2003). This effect was also visible in our hands when the slightly 
different detergent Tween 20 was used (Figure 11). 
 
5.1.2 Binding of 4MU to BSA 
About 10 to 20% of the effective concentrations of 4MU were removed by 
binding to 0.1% BSA. This percentage remained stable in the range between 2 
to 160 µM of substrate. The linearity of fu for different concentrations of 
substrate is, therefore, in agreement with the data reported in (Rowland et al., 
2008). 
 
At the stage of completing my work, it was not yet possible to perform a full and 
accurate estimation of the fu, since there was still an open question of whether 
or not some 4MU is trapped with the BSA when it is precipitated by the addition 
of PCA. Comparing the concentration of 4MU in the feed to the original 
concentration, it seemed that 10% were still ‘trapped’ in albumin. The 
comparison between the original unfiltered concentration and the filtrate 
resulted in a fu of 0.7. 
 
In the previous article (Rowland et al. 2008), it was claimed that the fu for 4MU 
in presence of BSA was 0.89. This value could be almost achieved by us as 
well, if we only compared the filtrate with the feed in our system (fu = 0.81) and 
thereby overlook the residual binding of 4MU to albumin. Further studies have 
to be performed to establish the correct fu. 
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5.1.3 Washing insect cell membranes with BSA 
The results concerning membranes pretreatment with BSA revealed that the 
removal of the inhibitory factor can not be achieved in this way. One may 
suggest that if the inhibitor is a fatty acid, then following the removal of BSA 
there is further release of inhibitory fatty acids from the membranes. A 
pretreatment is therefore difficult, given by the impossibility of preventing the 
release of additional FA without affecting the activity of the UGTs. As seen in 
the experiment, a proper removal of all the inhibitor molecules that could be 
removed by BSA requires the presence of BSA during the reaction, namely the 
incubation of the membranes with the substrates. 
 
5.2 Kinetics 
5.2.1 Characterization of the UGTs inhibition 
According to previous studies (Rowland et al., 2008;  Uchaipichat et al., 2006;  
Raungrut et al., 2010;  Rowland et al., 2006), the addition of BSA increases the 
activity of all the tested UGTs. As reported in these publications, the effect was 
caused by removing a mixture of inhibitors (FAs) by albumin. The parameters 
Vmax and Km were, therefore, used to analyze the type of the inhibitors affecting 
our recombinant UGTs. 
 
All the substrate kinetics performed showed a significant increase of Vmax when 
BSA was added to the incubation mixture. This observation led to the 
assumption that the inhibitors removed by albumin were binding to another 
binding site than 4MU and Entacapone. UDPGA kinetics were therefore 
performed to test, whether or not the inhibitor was competing for the same 
binding site as UDPGA. Interestingly, also the Vmax of these kinetics were 
increased as a consequence of BSA addition. The inhibitors were therefore 
modulating the activity of the enzyme mainly through a third binding site. 
 
Since most of the isoforms expressed atypical kinetics at least in presence of 
BSA, it was not possible to compare the Km. This lack of information hindered 
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to establish whether the inhibitor was binding with prevalence to the free 
enzyme or to the ES complex. 
 
A significant use of this parameter was only possible for the substrate kinetics 
of UGT1A7 with Entacapone as the aglycone substrate and the UPDGA 
kinetics of the UGTs 1A7, 1A9 and 2A1 with 4MU. The increase of the Km in the 
presence of BSA suggested that in the glucuronidation of Entacapone by 
UGT1A7, the inhibitor was prevalently binding to the ES complex. In contrast, 
the data of the UDPGA kinetics showed that the inhibition was occurring prior 
to the binding of UDPGA. These results are, however, incomplete at this stage. 
 
Concluding, the data concerning the experiments with our recombinant UGTs 
1A7, 1A8, 1A9, 1A10, 2A1 and 2B15 indicated that BSA was removing a 
mixture of noncompetitive and/or mixed type inhibitors. 
 
Although this result seemed to be coherent through all our experiments, it was 
not fully consistent with the reported results regarding the effect of BSA on the 
activity of UGTs in vitro (Table 2). According to these publications, the mixture 
of inhibitors was acting competitively towards several substrates glucuronidated 
by the UGTs 1A9, 2B4 and 2B7. Only the glucuronidation of lamotrigine by the 
UGT1A4 seemed to be affected by a mixed type inhibitor (Rowland et al., 
2006). 
 
The most interesting data for the purpose of this thesis was the glucuronidation 
of 4MU by UGT1A9 reported in Rowland et al., 2008 (Table 12). In this 
publication the authors claimed, based on the observed decrease in Km and 
unchanged Vmax that BSA was removing a competitive inhibitor. They also 
analyzed the inhibitory effect of a mixture of fatty acids (oleic acid, arachidonic 
acid, linoleic acid) on the same system and got similar results. It is also 
reported by Tsoutsikos et al. 2004 that arachidonic and linoleic acid inhibited 
separately the glucuronidation of 4MU by UGT1A9 in a competitive manner. 
This inhibitory effect was also visible in human kidney cortical microsomes. 
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Table 12. Effect of BSA and fatty acids on UGT1A9, HLM and HKCM 
In contrast to the previously published reports, the glucuronidation of 4MU by 
our recombinant UGTs seemed to be affected by a mixed type inhibitor, visible 
as a significant increase of Vmax. This effect was, however, not present in the 
glucuronidation of 4MU by HLM (Table 8 and Figure 17). The slightly lowered 
Vmax and Km that we have detected could be explained by the contribution of 
different isoforms. 
Source Tested system Type of inhibition 
Our data   
4MU kinetics in the presence of 
BSA 
Recombinant UGT1A9 
expressed in Sf9 cells 
Mixed type 
 Human liver microsomes Slightly competitive 
Entacapone kinetics in the 
presence of BSA 
Recombinant UGT1A9 
expressed in Sf9 cells 
Mixed type 
 Human liver microsomes Mixed type 
Rowland et al., 2008   
4MU kinetics in the presence 
of BSA  
 
recombinant UGT1A9 
expressed in HEK293 
cells 
Competitive 
Rowland et al., 2007   
4MU kinetics inhibited by a 
mixture of oleic acid, linoleic 
acid and arachidonic acid 
HLM Competitive 
(but with slight 
decrease of Vmax) 
Tsoutsikos et al., 2004    
4MU kinetics inhibited by 
arachidonic or linoleic acid 
recombinant UGT1A9 
expressed in HEK293 
cells 
Competitive 
human kidney 
cortical microsomes 
Competitive 
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Nevertheless, the effect of BSA towards UGT1A9 in human liver microsomes 
could be evaluated by measuring the glucuronidation of Entacapone by HLM. 
This substance is glucuronidated in HLM almost exclusively by UGT1A9 
(Lautala et al., 2000).  
 
Our data showed that BSA was removing a mixed type inhibitor from the 
system, when the activity of recombinant UGT1A9 was tested towards 
Entacapone. Interestingly, this effect was also present in HLM and HIM when 
entacapone was the aglycone substrate, confirming the presence of mixed type 
inhibitors also in the more native systems. 
 
A possible reason for the apparent differences between our and the previously 
published results could be the use of a different recombinant UGT system. 
According to Rowland et al., 2007 and Marheineke et al., 1998, the amounts 
and percentages of fatty acids differ between HEK293, HLM and Sf9 cells. The 
types of inhibition have only been tested for arachidonic acid and linoleic acid 
separately (Tsoutsikos et al., 2004) and for a mixture of oleic acid, arachidonic 
acid and linoleic acid (Rowland et al., 2007). Kinetics in the presence of 
palmitoleic acid, for example, an inhibitor of at least UGT1A9 and 2B7 
(Tsoutsikos et al., 2004), have not been performed yet. Interestingly, 
palmitoleic acid is the second most abundant FA in Sf9 cells, but its presence 
in HLM and HEK293 cells is minor in comparison to other FAs. 
 
Another explanation for the differences between the current and previous 
studies could be that the type of inhibition is isoform and/or substrate 
dependent. The effect of BSA on UGTs 1A7, 1A8, 1A10, 2A1 and 2B15 has not 
been studied or published so far. Also the kinetics of UGT1A9 with Entacapone 
has not been performed previously. The published data for the glucuronidation 
of lamotrigine by UGT1A4 (Rowland et al., 2006), where BSA seems to remove 
a mixed type inhibitor, is in line with our results, but this is not an evidence 
since a different UGT and a different substrate were examined. Still, it shows 
that not all inhibitions are the same, even when inhibitors removal by BSA is 
tested. 
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5.2.2 Atypical kinetics  
As previously observed (Table 2) the addition of BSA seems to increase or 
even unmask the presence of two site model kinetics in almost all the tested 
isoforms (Table 13). By removing the inhibitor, the substrate can bind also to a 
second site, affecting the glucuronidation of another molecule of the same 
substrate. The binding of 4MU to a second site seemed to inhibit the activity of 
all the tested isoforms, while Entacapone was inducing an autoactivation. An 
additional (partial) substrate inhibition occurred also in the glucuronidation of 
Entacapone by UGT1A8 and 1A9. 
 
Table 13. Changes of the kinetics as a consequence of BSA addition  
Kinetic models: MM= Michaelis Menten ; SI= Substrate Inhibition; PI= Partial Inhibition; 
AA= Autoactivation 
Isoform 
4MU  ENTACAPONE 
Control 0.1% BSA  Control 0.1% BSA 
1A7 Slight PI Strong PI  MM MM 
1A8 N.A. N.A.  AA + SI AA + SI 
1A9 Slight PI Strong PI  SI AA + PI 
1A10 MM PI  Slight AA AA 
2A1 MM PI  N.A. N.A. 
2B15 MM PI  N.A. N.A. 
HIM N.A. N.A.  Slight AA AA 
HLM MM MM  SI AA + PI 
 
Interestingly, the kinetics of Entacapone glucuronidation by HLM was similar to 
the kinetics of this reaction by recombinant UGT1A9 (Figure 20). In both 
systems BSA was increasing or unmasking an autoactivation with subsequent 
partial inhibition. As already described, Entacapone is glucuronidated in HLM 
almost exclusively by UGT1A9 (Lautala et al., 2000). Hence, this result proved 
that our system is comparable to the commercial available HLM. 
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The removal of the inhibitors is therefore not only increasing the activity of the 
enzyme, it is also releasing a second binding site for the substrate. Based on 
the published data, it can be assumed that the inhibitors in our system are FAs. 
Since FAs can act as competitive inhibitors (Rowland et al., 2006; Rowland et 
al., 2008a; Rowland et al., 2009; Uchaipichat et al., 2006; Raungrut et al., 
2010), while they are also substrates for the UGTs (Little et al., 2002; Turgeon 
et al., 2003; Little et al., 2004), it can be concluded that both, the catalytic and 
the inhibitory sites are capable of binding both the substrate and the FAs. This 
leads to the assumption that both binding sites are therefore similar to each 
other. 
 
It was previously discussed extensively that UGTs may be oligomeric enzymes, 
and that the occurrence of homo- and hetero- dimers is likely (Finel and 
Kurkela, 2008). According to that, the above mentioned inhibitory site could be 
the catalytic site of the second half of the dimer (Figure 23). This would 
implicate a reciprocal influence between the two halves of the dimer. In this 
case, the inhibitor would act as competitive and mixed type inhibitor towards 
the glucuronidation of the same substrate and the same enzyme.  
 
Figure 23. Scheme of a dimer, where substrate and FAs compete for the same 
binding sites. The addition of BSA removes the FAs and facilitates the binding of 
substrate. 
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As visible in Figure 24, it is not possible to ascertain a competitive inhibition if a 
mixed type inhibitor is affecting the system at the same time. The additional 
competitive inhibition in our system could be therefore masked by the presence 
of a mixed type inhibition. 
 
 
Figure 24. Influence of inhibitors on Km and Vmax 
 
This hypothesis could be also used to explain the particular results obtained for 
the glucuronidation of 4MU by HLM. The difference between the isoforms 
present in the microsomes and the recombinant isoforms is that while the latter 
can only form homo- dimers, hetero- dimers could occur in HLM as well. It 
might be that 4MU acts as a stronger inhibitor towards its own glucuronidation 
than the FA, when two different isoforms are linked to a dimer. In this case, 
BSA is increasing the chance for 4MU to bind also to the second site and is 
hence decreasing the activity of the enzyme. The lowered Vmax would be given 
by the mixed type inhibition by 4MU and the decreased Km would indicate the 
removal of the competitively inhibiting FA. Further experiments are, however, 
needed to confirm this assumption. 
 
Since it is not fully confirmed that UGTs form dimers, it is not possible to 
exclude the presence of a second binding site for the inhibitor and the substrate 
on the same enzyme/monomer. 
 
Mixed type inhibition 
Competitive inhibition 
Km 
Vmax 
Effects of BSA on in vitro glucuronidation studies using human microsomes and recombinant enzymes 
 
64 
6 Conclusion 
 
Our results showed that, in contrast to previously published findings, a mixed 
type inhibitor was affecting our recombinant UGTs 1A7, 1A8, 1A9, 1A10, 2A1 
and 2B15, when the glucuronidation of both 4MU and Entacapone was tested. 
This outcome was also visible in the glucuronidation of Entacapone by the 
commercial available HLM and HIM. The glucuronidation of 4MU by HLM, 
however, demonstrated a particular influence of BSA. While Km was decreased 
(suggesting the removal of a competitive inhibitor), Vmax was also lower, 
indicating the appearance of a mixed type inhibitor. We tried to explain this 
outcome by supposing that 4MU was in this case acting as a stronger mixed 
type inhibitor towards its own glucuronidation, than FAs. 
 
Another interesting result was the appearance of two-site model kinetics by the 
addition of BSA to almost all the tested UGT isoforms. We observed that this 
effect was also visible in previous publications (Table 2). Noticing, that the 
substrates and the FAs were both binding to two sites in this model, we 
suggest that these sites were the identical catalytic sites in a UGT dimer (Finel 
and Kurkela, 2008). This would implicate that both halves of the dimer are 
influencing the activity of each other. 
 
Our suggestions to explain the differences between our results and the 
previous ones are based on the use of different expression systems for 
producing recombinant UGTs, something that might lead to:  
 
- different inhibitors are present in our system (different concentrations of 
FAs or additional presence of other inhibitors) 
- the inhibition pattern is substrate and/or isoform dependent 
- a different distribution of monomers and dimers can occur 
 
Nevertheless, these hypotheses have still to be proven by the quantification of 
FAs in our system and following kinetics in presence of each FA. 
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We confirmed with our results that BSA increases the activity of UGTs 1A7, 
1A8, 1A9, 1A10, 2A1 and 2B15. This reinforces the recommendation to 
consider the inhibitors present in the systems when in vitro tests are performed 
with UGTs. 
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